Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adolescent ADHD Patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Methylphenidate (Primary)
Indications Attention-deficit hyperactivity disorder
Focus Registrational; Therapeutic Use
Sponsors Rhodes Pharmaceuticals

Most Recent Events

01 Nov 2021 Results published in the Journal of Child and Adolescent Psychopharmacology
16 Jan 2020 Results published in Adlon Therapeutics L.P.and Purdue Pharma media release Media Release
16 Jan 2020 According to a Adlon Therapeutics L.P.and Purdue Pharma media release, data from this trial will be presented at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting in Washington D.C.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com